catheter clinical trial results positive, page-2

Gidday Flloyd

A belated post: here's the latest commentary from Wilson HTM. If you could tell me how to attach a report on HC then I can post the report...perhaps I'll post in on S S. Have a look there.

We maintain our BUY recommendation and 12-month price target of $2.04, on the back of successful clinical trials, indicating that CXD’s modular cardiac catheters are capable of diagnosing heart arrhythmias, show good
quality signals and that handling characteristics were acceptable compared to clinician’s expectations. We believe the company is on track to submit applications for EU CE Mark and to the TGA for marketing approval within the next 4-8 weeks. The company has already appointed a distributor in the UK , and we expect more appointments to be made in the near term.